BR100 Decreased By (-0.7%)
BR30 Decreased By (-0.77%)
KSE100 Decreased By (-0.53%)
KSE30 Decreased By (-0.55%)
BECO 5.66 Decreased By ▼ -0.02 (-0.35%)
BML 63.53 Decreased By ▼ -1.31 (-2.02%)
BOP 33.60 No Change ▼ 0.00 (0%)
CNERGY 8.14 Decreased By ▼ -0.10 (-1.21%)
DCL 11.40 Increased By ▲ 0.05 (0.44%)
FCCL 52.18 Decreased By ▼ -0.73 (-1.38%)
FCSC 5.52 No Change ▼ 0.00 (0%)
FFL 17.75 Decreased By ▼ -0.05 (-0.28%)
FNEL 1.30 No Change ▼ 0.00 (0%)
HUMNL 11.20 Decreased By ▼ -0.04 (-0.36%)
KEL 7.88 Decreased By ▼ -0.09 (-1.13%)
KOSM 5.63 Increased By ▲ 0.19 (3.49%)
MLCF 85.75 Decreased By ▼ -0.26 (-0.3%)
NBP 184.00 Decreased By ▼ -1.00 (-0.54%)
PACE 11.68 Decreased By ▼ -0.34 (-2.83%)
PAEL 40.30 Increased By ▲ 0.09 (0.22%)
PIAHCLA 25.87 Increased By ▲ 0.14 (0.54%)
PIBTL 17.05 Decreased By ▼ -0.27 (-1.56%)
PPL 224.70 Decreased By ▼ -0.60 (-0.27%)
PRL 34.60 Increased By ▲ 0.22 (0.64%)
PTC 64.19 Decreased By ▼ -1.27 (-1.94%)
SEARL 90.40 Decreased By ▼ -0.11 (-0.12%)
SSGC 26.56 Decreased By ▼ -0.20 (-0.75%)
TELE 9.08 Increased By ▲ 0.12 (1.34%)
THCCL 67.23 Decreased By ▼ -2.21 (-3.18%)
TPLP 11.40 Increased By ▲ 0.09 (0.8%)
TREET 24.70 Increased By ▲ 0.15 (0.61%)
TRG 71.14 Decreased By ▼ -0.53 (-0.74%)
WAVES 10.91 Decreased By ▼ -0.54 (-4.72%)
WTL 1.27 Decreased By ▼ -0.01 (-0.78%)

A stem cell transplant works better than medicine to extend the lives of people with scleroderma, an autoimmune disease in which the skin hardens and organs break down, researchers said on Wednesday. The findings in the New England Journal of Medicine point to a new way of treating the incurable disease, which affects some 2.5 million people worldwide, most of them women of childbearing age.
"Scleroderma hardens the skin and connective tissues and in its severe form leads to fatal organ failure, most often the lungs," said lead author Keith Sullivan, professor of medicine and cellular therapy at Duke University. "In these severe cases, conventional drug therapies are not very effective long-term, so new approaches are a priority." The study randomly assigned 36 scleroderma patients in the United States and Canada to receive a stem cell transplant. First they had to undergo high-dose chemotherapy and whole-body radiation to fully wipe out their malfunctioning immune system.
Then they were re-infused with their own blood stem cells that had been removed and treated to eliminate the faulty white blood cells. Another 39 patients were randomly assigned to get 12 monthly intravenous injections of cyclophosphamide, which is the conventional immune suppressing treatment for severe scleroderma.

Copyright Agence France-Presse, 2018

Comments

Comments are closed for this article.